Acadia Pharmaceuticals (ACAD) Short-term Investments (2010 - 2026)

Acadia Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $569.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 22.71% year-over-year to $569.2 million; the TTM figure through Mar 2026 stood at $569.2 million (up 22.71% YoY), while the FY2025 annual figure was $642.0 million, up 47.11% from the prior year.
• Short-term Investments was $569.2 million for Q1 2026 at Acadia Pharmaceuticals, down from $642.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $642.0 million in Q4 2025 to a low of $112.0 million in Q1 2023.
• Historically, Short-term Investments has averaged $365.1 million across 5 years, with a median of $302.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments plunged 53.55% in 2023, then soared 137.35% in 2024.
• A 5-year view of Short-term Investments shows it stood at $302.0 million in 2022, then decreased by 17.14% to $250.2 million in 2023, then jumped by 74.42% to $436.4 million in 2024, then soared by 47.11% to $642.0 million in 2025, then dropped by 11.33% to $569.2 million in 2026.
• The last three Short-term Investments figures came in at $569.2 million (Q1 2026), $642.0 million (Q4 2025), and $589.0 million (Q3 2025), per Business Quant data.